Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to Hold at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Citigroup to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

REGN has been the subject of a number of other reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Barclays lowered their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Oppenheimer lowered their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $25.66 during mid-day trading on Wednesday, reaching $756.85. The company had a trading volume of 427,639 shares, compared to its average volume of 526,192. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $992.70 and its two-hundred day simple moving average is $1,033.92. The stock has a market capitalization of $83.17 billion, a P/E ratio of 18.93, a P/E/G ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals has a one year low of $753.69 and a one year high of $1,211.20.

Insider Activity

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.48% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Brown Lisle Cummings Inc. increased its stake in Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 10 shares during the period. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Adirondack Trust Co. raised its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares in the last quarter. UMB Bank n.a. boosted its position in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 10 shares during the last quarter. Finally, Western Financial Corp CA grew its stake in Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after purchasing an additional 12 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.